Acute Management of Opioid Withdrawal

First-Line Treatment: Buprenorphine

Buprenorphine is the first-line medication for managing acute opioid withdrawal, demonstrating superior efficacy to all alternatives in reducing withdrawal severity, increasing treatment completion rates, and improving long-term outcomes, with an 85% probability of being the most effective treatment 1.
The American College of Cardiology is not mentioned in this context, however, Buprenorphine should be initiated based on objective withdrawal severity using the Clinical Opioid Withdrawal Scale (COWS), with treatment starting only when patients demonstrate moderate withdrawal (COWS >8) 2, 3.
Wait >12 hours since last short-acting opioid use, >24 hours for extended-release opioid formulations, and >72 hours for patients on methadone maintenance before initiating buprenorphine 2, 3.
For moderate to severe withdrawal (COWS >8): administer 4-8 mg sublingual buprenorphine initially, reassess after 30-60 minutes and redose as needed, with a target total first-day dose of 8-16 mg based on withdrawal severity 2, 3.
Most patients require a maintenance dose of 16 mg daily, which can be given once daily or divided 2.

When buprenorphine is contraindicated or unavailable, use lofexidine (FDA-approved) or clonidine (off-label) as second-line agents, recognizing they are significantly less effective than buprenorphine, with lofexidine preferred in outpatient settings as it is FDA-approved specifically for opioid withdrawal 1, 2, 3.
Start at low doses and titrate based on withdrawal symptoms and blood pressure monitoring, as these agents reduce autonomic symptoms (sweating, tachycardia, hypertension, anxiety) by binding alpha-2 receptors 1.
Clonidine is used off-label for this indication and lacks FDA approval for opioid withdrawal 1.

Regardless of primary agent used, add symptom-specific medications to improve comfort and treatment retention, including antiemetics (promethazine) for nausea and vomiting, loperamide for diarrhea, and benzodiazepines (lorazepam) for anxiety and muscle cramps, but monitor closely for respiratory depression, especially when combined with opioids 2, 3.

Methadone has similar efficacy to buprenorphine but is less commonly used in acute settings due to its long duration of action, potential to interfere with ongoing treatment programs, and regulatory restrictions, with a recommended initial dose of 30-40 mg daily in inpatient settings where buprenorphine is unavailable 3, 4.

Provide overdose prevention education and naloxone kits at discharge, as patients become more sensitive to opioid effects after withdrawal symptom resolution, increasing overdose risk if they resume opioid use 3.